AARC and PALISI Clinical Practice Guideline: Pediatric Critical Asthma

dc.contributor.authorWhite, Benjamin R.
dc.contributor.authorMiller, Andrew G.
dc.contributor.authorBaker, Joyce
dc.contributor.authorBasnet, Sangita
dc.contributor.authorCarroll, Christopher L.
dc.contributor.authorCraven, Hannah J.
dc.contributor.authorDalabih, Abdallah
dc.contributor.authorFitzpatrick, Anne M.
dc.contributor.authorGlogowski, Joel
dc.contributor.authorIrazuzta, Jose Enrique
dc.contributor.authorKapuscinski, Christine A.
dc.contributor.authorLenox, Jesslyn
dc.contributor.authorLovinsky-Desir, Stephanie
dc.contributor.authorMaue, Danielle K.
dc.contributor.authorMoody, Gerald
dc.contributor.authorNewth, Christopher
dc.contributor.authorRehder, Kyle J.
dc.contributor.authorSochet, Anthony A.
dc.contributor.authorSaid, Sana J.
dc.contributor.authorWillis, L. Denise
dc.contributor.authorWhipple, Elizabeth C.
dc.contributor.authorGoodfellow, Lynda
dc.contributor.authorAbu-Sultaneh, Samer
dc.date.accessioned2025-05-19T18:35:34Z
dc.date.available2025-05-19T18:35:34Z
dc.date.issued2025
dc.description.abstractTo address the lack of guidance for clinicians in their care of children with critical asthma, a multidisciplinary team of medical providers used Grading of Recommendations, Assessment, Development, and Evaluation methodology to make the following recommendations: 1. We suggest the use of continuous inhaled short-acting β agonist (SABA) over frequent intermittent SABA in children treated for critical asthma. (Conditional recommendation, very low certainty of evidence) 2. We suggest the use of either high- or low-dose continuous inhaled SABA regimens in children treated for critical asthma. (Conditional recommendation, very low certainty of evidence) 3. We suggest the use of either dexamethasone or methylprednisolone (or an equivalent dose of prednisone/prednisolone) for children treated for critical asthma. (Conditional recommendation, very low certainty of evidence) 4. We suggest the use of intravenous (IV) magnesium (intermittent or continuous) as an adjunct therapy in children treated for critical asthma. (Conditional recommendation, low certainty of evidence) 5. We cannot recommend for or against the use of IV methylxanthines as an adjunct therapy in children treated for critical asthma. (Conditional recommendation, very low certainty of evidence) 6. We suggest the use of an IV SABA infusion as an adjunct therapy in children treated for critical asthma. (Conditional recommendation, low certainty of evidence) 7. We cannot recommend for or against the application of high-flow nasal cannula versus conventional oxygen therapy in children presenting with critical asthma with persistent hypoxemia and/or respiratory distress. (Conditional recommendation, very low certainty of evidence) 8. We suggest the use of bi-level positive airway pressure over conventional oxygen therapy in children presenting with critical asthma with persistent hypoxemia and/or respiratory distress. (Conditional recommendation, very low certainty of evidence) 9. We cannot recommend for or against the application of bi-level positive airway pressure over high-flow nasal cannula for children hospitalized with critical asthma with persistent hypoxemia and/or respiratory distress. (Conditional recommendation, very low certainty of evidence) 10. We cannot recommend for or against the application of heliox in children treated for critical asthma. (Conditional recommendation, very low certainty of evidence) 11. We suggest the use of a dedicated protocol or pathway for managing children treated for critical asthma. (Conditional recommendation, low certainty of evidence).
dc.identifier.citationWhite BR, Miller AG, Baker J, Basnet S, Carroll CL, Craven H, Dalabih A, Fitzpatrick AM, Glogowski J, Irazuzta JE, Kapuscinski CA, Lenox J, Lovinsky-Desir S, Maue DK, Moody G, Newth C, Rehder KJ, Sochet AA, Said SJ, Willis LD, Whipple EC, Goodfellow L, Abu-Sultaneh S. AARC and PALISI Clinical Practice Guideline: Pediatric Critical Asthma. Respir Care. 2025 May;70(5):593-609. doi: 10.1089/respcare.12897. PMID: 40323974.
dc.identifier.urihttps://hdl.handle.net/1805/48237
dc.language.isoen_US
dc.publisherMary Ann Liebert, Inc.
dc.relation.isversionof10.1089/respcare.12897
dc.subjectInhalation Administration
dc.subjectAdrenergic beta-Agonists
dc.subjectAnti-Asthmatic Agents
dc.subjectAsthma
dc.subjectPediatrics
dc.subjectaminophylline
dc.subjectterbutaline
dc.subjectstatus asthmaticus
dc.subjectnoninvasive ventilation
dc.subjectnoninvasive respiratory support
dc.subjectmagnesium
dc.subjecthigh-flow nasal cannula
dc.subjectheliox
dc.subjectglucocorticoids
dc.subjectevidenced-based guideline
dc.subjectclinical practice guideline
dc.subjectchildren
dc.subjectbronchodilator
dc.subjectbi-level positive airway pressure
dc.titleAARC and PALISI Clinical Practice Guideline: Pediatric Critical Asthma
dc.typeArticle
Files
Original bundle
Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
AARC and PALISI Clinical Practice Guideline - Pediatric Critical Asthma.pdf
Size:
790.1 KB
Format:
Adobe Portable Document Format
Description:
Article
No Thumbnail Available
Name:
respcare.12897_supplementary_data.docx
Size:
2.11 MB
Format:
Microsoft Word XML
Description:
Supplementary Materials
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: